Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wound wash saline comment

This article was originally published in The Tan Sheet

Executive Summary

FDA's proposal to declare wound wash saline products unapproved new drugs is misguided, given the agency's history of regulating wound cleansers as medical devices, the Washington office of King & Spalding says in a Sept. 16 letter to FDA. In a June 19 Federal Register notice, the agency includes wound wash saline in a list of drug ingredients and products proposed to not be generally recognized as safe and effective and to require an approved new drug application for future marketing (1"The Tan Sheet" June 23, 2008, p. 7). Since the Center for Devices and Radiological Health regards such sterile wash products as functioning through a physical mechanism rather than chemical or metabolic action, King & Spalding encourages FDA to clarify in a final rule "that not all 'wound wash saline' products are 'drugs,' much less 'new drugs.'

You may also be interested in...

FDA Proposes Aloe Vera, Other Ingredients For Non-GRASE List

FDA has proposed adding aloe vera products labeled for analgesic and antimicrobial uses to its list of ingredients and categories that lack adequate data to establish their safety and effectiveness

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts